Business
Novartis Cholesterol Trial Setback Casts Shadow Over Multi-Billion Dollar Drug Race
Novartis' pelacarsen trial failed to improve cardiovascular outcomes despite lowering Lp(a), raising doubts in the race against competitors Amgen and Eli Lilly.